BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,167,414 | -18.6% | 90,604 | -2.3% | 0.02% | -15.4% |
| Q2 2023 | $7,573,631 | +10.0% | 92,780 | 0.0% | 0.03% | +4.0% |
| Q1 2023 | $6,883,348 | -10.5% | 92,780 | 0.0% | 0.02% | -13.8% |
| Q4 2022 | $7,689,606 | +20.2% | 92,780 | +312.0% | 0.03% | +11.5% |
| Q3 2022 | $6,396,000 | -18.1% | 22,521 | 0.0% | 0.03% | -13.3% |
| Q2 2022 | $7,807,000 | -19.9% | 22,521 | 0.0% | 0.03% | -3.2% |
| Q1 2022 | $9,752,000 | -16.3% | 22,521 | 0.0% | 0.03% | -8.8% |
| Q4 2021 | $11,651,000 | +6.8% | 22,521 | 0.0% | 0.03% | 0.0% |
| Q3 2021 | $10,913,000 | +7.8% | 22,521 | +0.2% | 0.03% | +3.0% |
| Q2 2021 | $10,121,000 | +8.7% | 22,479 | -7.8% | 0.03% | 0.0% |
| Q1 2021 | $9,312,000 | +9.7% | 24,381 | -8.8% | 0.03% | +10.0% |
| Q4 2020 | $8,488,000 | +22.1% | 26,730 | -4.8% | 0.03% | +7.1% |
| Q3 2020 | $6,953,000 | -7.1% | 28,068 | -1.0% | 0.03% | -9.7% |
| Q2 2020 | $7,484,000 | – | 28,341 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brown Capital Management | 2,119,107 | $256,179,000 | 3.12% |
| STONE RUN CAPITAL, LLC | 42,925 | $5,189,000 | 2.67% |
| 440 INVESTMENT GROUP, LLC | 27,820 | $3,363,000 | 2.56% |
| Summit Creek Advisors LLC | 106,517 | $12,877,000 | 2.54% |
| MAIRS & POWER INC | 1,444,480 | $174,623,000 | 2.10% |
| QUANTUM CAPITAL MANAGEMENT | 57,094 | $6,902,000 | 1.63% |
| Select Equity Group, L.P. | 1,709,914 | $206,711,503,000 | 1.57% |
| FRIESS ASSOCIATES LLC | 144,610 | $17,482,000 | 1.53% |
| Tygh Capital Management, Inc. | 61,813 | $7,473,000 | 1.49% |
| First Light Asset Management, LLC | 38,654 | $4,673,000 | 1.48% |